Federico Simonetta Selected Research

Infections

1/2023	Longitudinal Detection of Twenty DNA and RNA Viruses in Allogeneic Hematopoietic Stem Cell Transplant Recipients Plasma.
1/2020	Torque Teno Virus as a Potential Biomarker for Complications and Survival After Allogeneic Hematopoietic Stem Cell Transplantation.
1/2016	T-bet and Eomesodermin in NK Cell Development, Maturation, and Function.
1/2016	Immunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell Transplantation.
11/2015	NK Cell Functional Impairment after Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Reduced Levels of T-bet and Eomesodermin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Federico Simonetta Research Topics

Disease

20	Neoplasms (Cancer) 05/2024 - 11/2015
10	Graft vs Host Disease (Graft-Versus-Host Disease) 02/2024 - 01/2016
5	Hematologic Neoplasms (Hematological Malignancy) 01/2024 - 01/2017
5	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2023 - 01/2021
5	Infections 01/2023 - 11/2015
3	Hematologic Diseases (Blood Diseases) 12/2023 - 01/2022
3	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2018 - 05/2015
2	Disease Progression 01/2023 - 01/2019
2	Colorectal Neoplasms (Colorectal Cancer) 05/2022 - 03/2006
2	Bone Marrow Failure Disorders 01/2022 - 01/2016
2	Inflammation (Inflammations) 01/2019 - 01/2016
2	Brain Diseases (Brain Disorder) 01/2016 - 01/2013
2	HIV Infections (HIV Infection) 10/2014 - 05/2012
1	cell-associated neurotoxicity 05/2024
1	Melanoma (Melanoma, Malignant) 05/2024
1	Hodgkin Disease (Hodgkin's Disease) 01/2024
1	Residual Neoplasm 12/2023
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2023
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2023
1	Pathologic Complete Response 01/2023
1	Neuroinflammatory Diseases 01/2023
1	Leukemia 01/2023
1	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 11/2022
1	Lymphoma (Lymphomas) 05/2022
1	Oncogene Addiction 01/2022
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2022
1	Experimental Melanoma 06/2020
1	Breast Neoplasms (Breast Cancer) 01/2019
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2019
1	Psychomotor Agitation (Akathisia) 01/2018
1	Lupus Nephritis 01/2017
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 07/2015
1	Atrial Fibrillation 01/2013
1	Abscess 01/2013
1	Sarcoma (Soft Tissue Sarcoma) 04/2012
1	Neuroblastoma 04/2012
1	Carcinoma (Carcinomatosis) 03/2006

Drug/Important Bio-Agent (IBA)

5	Chimeric Antigen ReceptorsIBA 05/2024 - 06/2020
3	Transcription Factors (Transcription Factor)IBA 01/2023 - 10/2014
2	AntigensIBA 12/2023 - 06/2020
2	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2019
2	Rituximab (Mabthera)FDA Link 01/2017 - 07/2015
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2024
1	pembrolizumabIBA 01/2024
1	Brentuximab VedotinIBA 01/2024
1	Interleukin-3 (Interleukin 3)IBA 12/2023
1	Immunoconjugates (Immunoconjugate)IBA 12/2023
1	Monoclonal AntibodiesIBA 12/2023
1	CCAAT-Enhancer-Binding ProteinsIBA 01/2023
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2023
1	fms-Like Tyrosine Kinase 3IBA 01/2023
1	LipidsIBA 01/2023
1	Sorafenib (BAY 43-9006)FDA Link 01/2023
1	Triggering Receptor Expressed on Myeloid Cells-1IBA 01/2023
1	defibrotideIBA 11/2022
1	Firefly LuciferasesIBA 05/2022
1	Granzymes (Granzyme)IBA 05/2022
1	trametinibIBA 01/2022
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022
1	venetoclaxIBA 11/2021
1	AMP-Activated Protein KinasesIBA 11/2021
1	Surface Antigens (Surface Antigen)IBA 06/2020
1	Thymidine KinaseIBA 06/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	Nucleic AcidsIBA 01/2019
1	Inosine Triphosphate (ITP)IBA 01/2019
1	LigandsIBA 01/2019
1	Tumor Biomarkers (Tumor Markers)IBA 01/2019
1	LuciferasesIBA 01/2019
1	belimumabIBA 01/2017
1	Imipenem Drug Combination Cilastatin (Primaxin)FDA Link 01/2016
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2016
1	Prostaglandins FIBA 01/2016
1	Fas Ligand Protein (Fas Ligand)IBA 01/2016
1	InterferonsIBA 01/2016
1	Ciprofloxacin (Cipro)FDA LinkGeneric 01/2013
1	Metronidazole (Metric)FDA LinkGeneric 01/2013
1	Cyclin-Dependent Kinase Inhibitor p16IBA 04/2012
1	alpha-MSHIBA 04/2012
1	Type 1 Melanocortin ReceptorIBA 04/2012
1	Cyclin-Dependent Kinase 4IBA 04/2012
1	Irinotecan (Camptosar)FDA LinkGeneric 03/2006
1	Topoisomerase I InhibitorsIBA 03/2006

Therapy/Procedure

12	Hematopoietic Stem Cell Transplantation 02/2024 - 05/2015
10	Therapeutics 05/2024 - 10/2014
8	Immunotherapy 05/2024 - 01/2020
5	Cell Transplantation 01/2023 - 01/2017
4	Transplantation 01/2024 - 01/2020
2	Stem Cell Transplantation 01/2021 - 01/2018
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 12/2021
1	Cell- and Tissue-Based Therapy (Cell Therapy) 06/2020
1	Highly Active Antiretroviral Therapy (HAART) 05/2012
1	Aftercare (After-Treatment) 03/2006